Azitra

Azitra, Inc. is a clinical-stage biopharmaceutical company specializing in precision dermatology, with a focus on developing innovative therapies for a wide range of skin diseases. Founded in 2014 and headquartered in Branford, Connecticut, the company leverages advanced scientific approaches such as genetic engineering, proteomics, and microbiome... research to create targeted treatments. Its core strategy involves the use of engineered proteins and live biotherapeutic products, including genetically modified bacteria designed to restore or enhance the skins natural functions. Azitra has built a proprietary platform that combines a large microbial library of over 1,500 bacterial strains with artificial intelligence and machine learning tools to identify and develop effective therapeutic candidates. The companys pipeline includes treatments for conditions such as Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris. By focusing on the skin microbiome and engineered strains of Staphylococcus epidermidis, Azitra aims to deliver highly targeted and personalized dermatological treatments. With ongoing clinical trials and strategic collaborations, the company is positioned to advance next-generation therapies that address unmet medical needs in dermatology.Read More